Last updated: 6 March 2023 at 11:42am EST

Marc Becker Net Worth




The estimated Net Worth of Marc A. Becker is at least $3.15 Million dollars as of 15 February 2023. Mr. Becker owns over 3,762 units of Concert Pharmaceuticals Inc stock worth over $1,036,733 and over the last 6 years he sold CNCE stock worth over $225,018. In addition, he makes $1,887,420 as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Concert Pharmaceuticals Inc.

Mr. Becker CNCE stock SEC Form 4 insiders trading

Marc has made over 8 trades of the Concert Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,762 units of CNCE stock worth $31,337 on 15 February 2023.

The largest trade he's ever made was selling 8,493 units of Concert Pharmaceuticals Inc stock on 30 January 2023 worth over $70,917. On average, Marc trades about 2,553 units every 65 days since 2019. As of 15 February 2023 he still owns at least 123,863 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Mr. Becker stock trades at the bottom of the page.





Marc Becker biography

Marc A. Becker serves as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer of the Company. Mr. Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as the Chief Financial Officer of CRISPR Therapeutics AG, a biotechnology company, from February 2016 to September 2017. From January 2012 to February 2016, Mr. Becker served as the Chief Financial Officer of rEVO Biologics, Inc., a biotechnology company. Prior to rEVO Biologics, Mr. Becker held roles of increasing responsibility at Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A., from 2001 to 2011, culminating in Vice President, Finance. Mr. Becker received a B.S. in Business Administration from the University of Massachusetts and an M.B.A. from Babson College and was licensed as a certified public accountant.

What is the salary of Marc Becker?

As the Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Concert Pharmaceuticals Inc, the total compensation of Marc Becker at Concert Pharmaceuticals Inc is $1,887,420. There are 2 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.



How old is Marc Becker?

Marc Becker is 48, he's been the Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Concert Pharmaceuticals Inc since 2019. There are 13 older and 2 younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.

What's Marc Becker's mailing address?

Marc's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V..., and Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.



What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.



What does Concert Pharmaceuticals Inc's logo look like?

Concert Pharmaceuticals Inc logo

Complete history of Mr. Becker stock trades at Concert Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
15 Feb 2023 Marc A. Becker
Chief Financial Officer
Sale 3,762 $8.33 $31,337
15 Feb 2023
123,863
30 Jan 2023 Marc A. Becker
Chief Financial Officer
Sale 8,493 $8.35 $70,917
30 Jan 2023
127,625
6 Jan 2023 Marc A. Becker
Chief Financial Officer
Sale 2,893 $7.25 $20,974
6 Jan 2023
136,118
14 Feb 2022 Marc A. Becker
Chief Financial Officer
Sale 3,762 $3.08 $11,587
14 Feb 2022
139,011
5 Jan 2022 Marc A. Becker
Chief Financial Officer
Sale 2,894 $3.20 $9,261
5 Jan 2022
61,173
16 Aug 2021 Marc A. Becker
Chief Financial Officer
Sale 7,304 $3.28 $23,957
16 Aug 2021
64,067
16 Feb 2021 Marc A. Becker
Chief Financial Officer
Sale 3,763 $7.32 $27,545
16 Feb 2021
71,371
17 Aug 2020 Marc A. Becker
Chief Financial Officer
Sale 2,875 $10.24 $29,440
17 Aug 2020
53,434


Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: